PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34535564-4	2021	Radioligand binding analysis performed with mouse S1P5 confirmed the potency loss is a consequence of a loss of affinity of ozanimod for mouse S1P5 and was restored with mutation of alanine 120 to threonine.	ozanimod	124-132	sphingosine-1-phosphate receptor 5	Mus musculus	50-54
34932238-1	2022	BACKGROUND: Ozanimod, a high selective sphingosine 1 phosphate (S1P) receptor (S1PR) 1/5 modulator was approved by the Food and Drug Administration for the treatment of adult patients with moderately to severely active ulcerative colitis.	ozanimod	12-20	sphingosine-1-phosphate receptor 1	Homo sapiens	79-88
34535564-1	2021	Ozanimod, a sphingosine-1 phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5), is approved for the treatment of relapsing multiple sclerosis (MS) in multiple countries.	ozanimod	0-8	sphingosine-1-phosphate receptor 1	Mus musculus	106-129
34535564-1	2021	Ozanimod, a sphingosine-1 phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5), is approved for the treatment of relapsing multiple sclerosis (MS) in multiple countries.	ozanimod	0-8	sphingosine-1-phosphate receptor 1	Mus musculus	131-135
34535564-1	2021	Ozanimod, a sphingosine-1 phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5), is approved for the treatment of relapsing multiple sclerosis (MS) in multiple countries.	ozanimod	0-8	sphingosine-1-phosphate receptor 5	Mus musculus	144-148
34535564-4	2021	Radioligand binding analysis performed with mouse S1P5 confirmed the potency loss is a consequence of a loss of affinity of ozanimod for mouse S1P5 and was restored with mutation of alanine 120 to threonine.	ozanimod	124-132	sphingosine-1-phosphate receptor 5	Mus musculus	143-147
34535564-6	2021	Hence, in the experimental autoimmune encephalomyelitis model, ozanimod exposures sufficient to engage S1P1, but not S1P5, resulted in reduced circulating lymphocytes, disease scores, and body weight loss; reduced inflammation, demyelination, and apoptotic cell counts in the spinal cord; and reduced circulating levels of the neuronal degeneration marker, neurofilament light.	ozanimod	63-71	sphingosine-1-phosphate receptor 1	Mus musculus	103-107
34535564-10	2021	Ozanimod can thus be used as a selective S1P1 agonist in mouse models of multiple sclerosis to define efficacies driven by S1P1 but not S1P5 Based on readouts for experimental autoimmune encephalomyelitis and cuprizone intoxication, S1P1 modulation is neuroprotective but S1P5 activity may be required for remyelination.	ozanimod	0-8	sphingosine-1-phosphate receptor 1	Mus musculus	41-45
34535564-10	2021	Ozanimod can thus be used as a selective S1P1 agonist in mouse models of multiple sclerosis to define efficacies driven by S1P1 but not S1P5 Based on readouts for experimental autoimmune encephalomyelitis and cuprizone intoxication, S1P1 modulation is neuroprotective but S1P5 activity may be required for remyelination.	ozanimod	0-8	sphingosine-1-phosphate receptor 1	Mus musculus	233-237
34535564-10	2021	Ozanimod can thus be used as a selective S1P1 agonist in mouse models of multiple sclerosis to define efficacies driven by S1P1 but not S1P5 Based on readouts for experimental autoimmune encephalomyelitis and cuprizone intoxication, S1P1 modulation is neuroprotective but S1P5 activity may be required for remyelination.	ozanimod	0-8	sphingosine-1-phosphate receptor 5	Mus musculus	272-276
33674268-7	2021	Ozanimod is metabolized by three primary pathways including aldehyde dehydrogenase and alcohol dehydrogenase, cytochrome P450 (CYP) isoforms 3A4, 1A1, and reductive metabolism by gut microflora.	ozanimod	0-8	aldo-keto reductase family 1 member A1	Homo sapiens	87-108
34007159-3	2021	Ozanimod is an oral drug belonging to the sphingosine-1-phosphate receptor (S1PR) modulator family recently approved in different countries for MS with active disease.	ozanimod	0-8	sphingosine-1-phosphate receptor 1	Homo sapiens	76-80
34007159-8	2021	This article retraces the itinerary leading to the approval of ozanimod for MS treatment and its peculiarities and potentiality inside the S1PR modulator family.	ozanimod	63-71	sphingosine-1-phosphate receptor 1	Homo sapiens	139-143
34340305-6	2021	Molecular docking revealed FDA drugs ozanimod, siponimod, teriflunomide, and phytochemicals; emodin; protoapigenone; and EGCG bound to EBNA1 with high affinities.	ozanimod	37-45	EBNA-1	Human gammaherpesvirus 4	135-140
35355429-0	2022	Identification of Trovafloxacin, Ozanimod, and Ozenoxacin as potent c-Myc G-quadruplex stabilizers to suppress c-Myc transcription and myeloma growth.	ozanimod	33-41	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	68-73
35355429-0	2022	Identification of Trovafloxacin, Ozanimod, and Ozenoxacin as potent c-Myc G-quadruplex stabilizers to suppress c-Myc transcription and myeloma growth.	ozanimod	33-41	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	111-116
32737072-9	2020	CONCLUSION: Ozanimod induced dose-dependent reductions in circulating B- and T-cell counts and differential effects on naive and memory CD4+ and CD8+ T cells and CD19+ B cells.	ozanimod	12-20	CD4 molecule	Homo sapiens	136-139
34011531-0	2021	Investigation into MAO B-mediated formation of CC112273, a major circulating metabolite of ozanimod, in humans and preclinical species: Stereospecific oxidative deamination of (S)-enantiomer of indaneamine (RP101075) by MAO B.	ozanimod	91-99	monoamine oxidase B	Homo sapiens	19-24
34011531-1	2021	Ozanimod, recently approved for treating relapsing MS, produced a disproportionate, active, MAO B-catalyzed metabolite (CC112273) that showed remarkable interspecies differences and led to challenges in safety testing.	ozanimod	0-8	monoamine oxidase B	Homo sapiens	92-97
33658933-2	2020	As a novel, orally available sphingosine 1-phosphate receptor modulator, ozanimod selectively binds to S1P1 and S1P5 receptor with high affinity, minimizing safety concerns caused by S1P3 receptor activation.	ozanimod	73-81	sphingosine-1-phosphate receptor 1	Homo sapiens	103-107
33658933-2	2020	As a novel, orally available sphingosine 1-phosphate receptor modulator, ozanimod selectively binds to S1P1 and S1P5 receptor with high affinity, minimizing safety concerns caused by S1P3 receptor activation.	ozanimod	73-81	sphingosine-1-phosphate receptor 5	Homo sapiens	112-116
32810927-2	2020	The latter is exploited in the approval and/or late-stage development of receptor-desensitizing agents targeting the S1P1 receptor in multiple sclerosis, such as siponimod, ozanimod and ponesimod.	ozanimod	173-181	sphingosine-1-phosphate receptor 1	Homo sapiens	117-121
32737072-9	2020	CONCLUSION: Ozanimod induced dose-dependent reductions in circulating B- and T-cell counts and differential effects on naive and memory CD4+ and CD8+ T cells and CD19+ B cells.	ozanimod	12-20	CD8a molecule	Homo sapiens	145-148
32737072-9	2020	CONCLUSION: Ozanimod induced dose-dependent reductions in circulating B- and T-cell counts and differential effects on naive and memory CD4+ and CD8+ T cells and CD19+ B cells.	ozanimod	12-20	CD19 molecule	Homo sapiens	162-166
32455907-6	2020	Electrophysiological studies with selective S1P1 (AUY954) and S1P5 (A971432) agonists suggested that S1P1 modulation is the main driver of the anti-excitotoxic activity mediated by ozanimod.	ozanimod	181-189	sphingosine-1-phosphate receptor 1	Mus musculus	101-105
32570252-11	2020	Ozanimod, an S1PR1 and S1PR5 inhibitor, has been successfully tested in initial studies in UC.	ozanimod	0-8	sphingosine-1-phosphate receptor 1	Homo sapiens	13-18
32570252-11	2020	Ozanimod, an S1PR1 and S1PR5 inhibitor, has been successfully tested in initial studies in UC.	ozanimod	0-8	sphingosine-1-phosphate receptor 5	Homo sapiens	23-28
31317509-11	2019	Similarly, ozanimod, an S1P1 and S1P5 receptor agonist, has shown early favorable results and is enrolling in phase III trials.	ozanimod	11-19	sphingosine-1-phosphate receptor 1	Homo sapiens	24-46
29608575-0	2018	Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus.	ozanimod	0-8	sphingosine-1-phosphate receptor 1	Mus musculus	32-37
29608575-0	2018	Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus.	ozanimod	0-8	sphingosine-1-phosphate receptor 5	Mus musculus	42-47
26990079-0	2016	Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.	ozanimod	0-8	sphingosine-1-phosphate receptor 1	Homo sapiens	31-65
26990079-0	2016	Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.	ozanimod	0-8	sphingosine-1-phosphate receptor 1	Homo sapiens	67-71
26990079-0	2016	Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.	ozanimod	0-8	sphingosine-1-phosphate receptor 5	Homo sapiens	90-94